Canada markets closed
  • S&P/TSX

    20,197.61
    +15.71 (+0.08%)
     
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • DOW

    31,261.90
    +8.80 (+0.03%)
     
  • CAD/USD

    0.7811
    +0.0021 (+0.27%)
     
  • CRUDE OIL

    110.62
    +0.34 (+0.31%)
     
  • BTC-CAD

    38,530.44
    +696.64 (+1.84%)
     
  • CMC Crypto 200

    671.70
    -1.67 (-0.25%)
     
  • GOLD FUTURES

    1,851.50
    +9.40 (+0.51%)
     
  • RUSSELL 2000

    1,773.27
    -2.95 (-0.17%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • NASDAQ futures

    11,954.75
    +114.00 (+0.96%)
     
  • VOLATILITY

    29.43
    +0.08 (+0.27%)
     
  • FTSE

    7,389.98
    +87.24 (+1.19%)
     
  • NIKKEI 225

    26,872.01
    +132.98 (+0.50%)
     
  • CAD/EUR

    0.7371
    -0.0001 (-0.01%)
     

Where Will Cassava Sciences Be in 1 Year?

·5 min read
Where Will Cassava Sciences Be in 1 Year?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting